Combining Azacitidine/Enasidenib to Enhance the Treatment of Newly Diagnosed IDH2-Mutant AML

February 07, 2020

Courtney D. DiNardo, MD, MSCE, explains the rationale for the phase II AG221-AML-005 trial.

Gemtuzumab Added to Induction Therapy Shows Limited EFS Benefit in NPM1-Mutant AML

January 31, 2020

Following the FDA approval of gemtuzumab ozogamicin with induction and consolidation therapy in newly diagnosed CD33-positive acute myeloid leukemia, investigators led by Richard F. Schlenk, MD, hypothesized that patients with NPM1-mutated acute myeloid leukemia, which occurs in 20% to 30% of the patient population, could also derive benefit from gemtuzumab.

DC Vaccine Demonstrates Feasibility and Safety in Phase I/II AML Study

January 16, 2020

The autologous dendric cell vaccine targeting Wilms tumor-1 antigens with or without preferentially Expressed Antigen in Melanoma was well tolerated and feasible in patients with acute myeloid leukemia, meeting the co-primary end points of the phase I/II clinical trial.

Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AML

January 11, 2020

Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo, in which the patient with acute myeloid leukemia harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib.

Enasidenib Plus Azacitidine Expands Treatment Landscape for IDH2-Mutant AML

January 08, 2020

In an interview with Targeted Oncology, Courtney D. DiNardo, MD, discussed the interim analysis results from the ongoing phase II trial evaluating the combination of enasidenib plus azacitidine in newly diagnosed patients with acute myeloid leukemia.

Investigational CD123 Antibody-Drug Conjugate Shows Preliminary Activity in AML and BPDCN

December 27, 2019

Results from a phase I/Ib trial showed revealed that preliminary activity was seen with IMGN632, an investigational anti-CD123 antibody-drug conjugate, given to patients with relapsed/refractory acute myelogenous leukemia or blastic plasmacytoid dendritic cell neoplasm, according to data presented at the 2019 ASH Annual Meeting.

Rapidly Progressing Acute Myeloid Leukemia

December 23, 2019

Rapidly Progressing Acute Myeloid Leukemia

Discussing Rationale of Azacitidine Plus Maintenance Therapy in AML

December 18, 2019

Naval Daver, MD, explains the rationale for the phase II QUAZAR trial, which assessed the efficacy and safety of azacitidine in patients with acute myeloid leukemia.

Treatment Options Expand for Older and Elderly Patients With AML

December 17, 2019

In an interview with Targeted Oncology, Pinkal Desai, MD, discussed the latest advancements in the treatment landscape for patients with AML, particularly for the older population. She also highlighted emerging treatment options that undergoing investigation now in clinical trials.

Enasidenib/Azacitidine Triggers Significant Responses in Newly Diagnosed IDH2-Mutated AML

December 17, 2019

Interim phase II trial data showed that the combination of enasidenib, an oral small molecule inhibitor of mutant IDH2 proteins, and azacitidine, significantly improves complete remission and overall responses in patients with newly diagnosed acute myeloid leukemia with IDH2 mutations compared with azacitidine alone, according to results presented at the 2019 American Society of Hematology Annual Meeting.